Apoptosis in metastatic cancer cells

Critical Reviews in Oncology/Hematology

Volumn 25, Issue 3, 1997, Pages 175-186

  Glinsky, Gennadi V ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL ADHESION; COLON CARCINOMA; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030946559     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00234-5     Document Type: Review

References (139)

1. Wyllie AH, Kerr JFR, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306, 1980.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462, 1995.
3. Williams GT and Smith CA. Molecular regulation on apoptosis: Genetic control on cell death. Cell 74:777-779, 1993.
4. Raff MC. Social control on cell survival and cell death. Nature 356:397-400, 1992.
5. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 65:1097-1098, 1991.
6. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6, 1994.
7. Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell 77:477-478, 1994.
8. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619-626, 1994.
9. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953-961, 1993.
10. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891-893, 1995.
11. vβ3 for angiogenesis. Science 264:569-572, 1994a.
12. 1 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994b.
13. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 127:537-546, 1994.
14. Bates RC, Buret A, van Helden DF, Horton MA, Burns GF. Apoptosis induced by inhibition of intercellular contact. J Cell Biol 125:403-415, 1994.
15. Fujita N, Kataoka S, Naito M, Heike Y, Boku N, Nakajima M, Tsuruo T. Suppression of T-lymphoma cell apoptosis by monoclonal antibodies raised against cell surface adhesion molecules. Cancer Res 53:5022-5027, 1993.
16. Kim WH, Schnaper HW, Nomizu M, Yamada Y, Kleinman HK. Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic tyr-ile-gly-ser-arg (YIGSR)-containing polypeptide from laminin. Cancer Res 54:5005-5010, 1994.
17. vβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 91:8856-8860, 1994.
18. 5β1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92:6161-6165, 1995.
19. Rak J, Mitsuhashi Y, Erdos V, Huang S, Filmus J, Kerbel RS. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol 131:1587-1598, 1995.
20. Glinsky GV, Glinsky VV. Apoptosis and metastasis: A superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 101:43-51, 1996.
21. Glinsky GV, Glinsky VV, Price JE. Association of aggressive metastatic phenotype with higher resistance to apoptosis. Proc Am Assoc Cancer Res 37:14, 1996.
22. Glinsky GV, Mossine VV, Price JE, Bielenberg D, Glinsky VV, Ananthaswamy HN, Feather MS. Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs. Clin Exp Metastasis 14:253-267, 1996.
23. Glinsky GV, Price JE, Glinsky VV, Kiriakova G, Mossine VV, Metcalf JB. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 56:5325-5329, 1996.
24. Fidler IJ. Selection of successive tumor lines for metastasis. Nature (New Biol) 242:148-149, 1973.
25. Fidler IJ. Biological behaviour of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35: 218-224, 1975.
26. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97:587-592, 1979.
27. Cohen JJ. Programmed cell death in the immune system. Adv Immunol 50:55-85, 1991.
28. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19 kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89:7742-7746, 1992.
29. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115, 1991.
30. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555-556, 1980.
31. van Golen KL, Owen-Schaub L, Price JE. Metastatic and nonmetastatic K-1735 melanoma cells differ in Fas-mediated apoptosis and growth response to lung-conditioned medium. Proc Am Assoc Cancer Res 37:79, 1996a.
32. van Golen KL, Risin S, Staroselsky A, Berger D, Tainsky MA, Pathak S, Price JE. Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clin Exp Metastasis 14:95-106, 1996b.
33. Risin SA, van Golen KL, Price JE, Pathak S. Further evidence for involvement of human chromosome 17 in control of metastatic phenotype in melanoma. Proc Am Assoc Cancer Res 37:79, 1996.
34. L. Proc Am Assoc Cancer Res 37:17, 1996.
35. Glinsky GV. Cell adhesion and metastasis: Is the site specificity of cancer metastasis determined by leukocyte-endothelial cell recognition and adhesion? Crit Rev Oncol/Hematol 14:229-278, 1993.
36. Raz A, Zhu D, Hogan V, Shah N, Raz T, Karakash R, Pazerini G, Carmi P. Evidence for the role of 34 kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 46:871-877, 1990.
37. Raz A, Lotan R. Endogenous galactoside-binding lectins: A new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 6:433-452, 1987.
38. Lotan R, Raz A. Lectins in cancer cells. Ann NY Acad Sci 551:385-398, 1988.
39. Meromsky L, Lotan R, Raz A. Implications of tumor cell surface lectins as mediators of cellular interactions and lung colonization. Cancer Res 46:5270-5275, 1986.
40. Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84:438-439, 1992.
41. Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactose-binding lectins correlates with neoplastic progression in the colon. Cancer 75:2818-2826, 1995.
42. Bresalier RS, Van P, Raz A. Expression of an endogenous galactose-binding lectin (galectin-3) correlates with malignancy of tumors in the CNS. Proc Am Assoc Cancer Res 37:81, 1996.
43. Bresalier RS, Byrd JC, Raz A. Colon cancer mucin is a major ligand for the β-galactoside binding protein galectin-3. Proc Am Assoc Cancer Res 37:81, 1996.
44. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma cell adhesion. Science 246:1303-1306, 1989.
45. Springer TA, Lasky LA. Sticky sugars for selectins. Nature 349:196-197, 1991.
46. Sawada R, Lowe, JB and Fukuda M. E-selectin-dependent adhesion efficiency of colonic carcinoma cells is increased by genetic manipulation of their cell surface lysosomal membrane glycoprtein-1 expression levels. J Biol Chem 268:12675-12681, 1993.
47. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 6:363-370, 1995.
48. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253-3259, 1994
49. McDonnell TJ, Meyn RF, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 6:53-60, 1995.
50. Reed JC. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin N Am 9:451-474, 1995.
51. van Golen KL, Berger DH, Tainsky MA, Risin S, Price JE. Mutations at codons 249 and 273 of human p53 gene confer metastatic potential to nonmetastatic mouse melanoma cells. Proc Am Assoc Cancer Res 37:79, 1996c.
52. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
53. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
54. Symonds H, Krail I, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. p53-dependent apoptosis supresses tumor growth progression in vivo. Cell 78:703-711, 1994.
55. Arends MJ, McGregor AH, Toft NJ, Brown EJH, Wyllie AH. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 68:1127-1133, 1994.
56. Wyllie AH. Apoptosis: The 1992 Frank Rose Memorial Lecture. Br J Cancer 67:205-208, 1992.
57. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E. Spandidos DA. Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 56:251-259, 1987.
58. Lin HJ, Eviner LV, Prendergast GC, White E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol Cell Biol 15:4536-4544, 1995.
59. Kinoshita T, Yokota T, Arai K, Miyajima A. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoetic cells. Oncogene 10:2207-2210, 1993.
60. Wyllie A. Apoptosis and the regulation of cell number in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 11:95-103, 1992.
61. Sarraf CE, Bowen ID. Proportions of mitotic and apoptotic cells in a range of untreated experimental tumours. Cell Tissue Kinet 21:45-49, 1988.
62. Columbano A, Ledda-Columbano GM, Rao PM, Rajalakshmi S, Sarma DS. Occurence of cell death (apoptosis) in preneoplastic and neoplastic liver cells: a sequential study. Am J Pathol 116:441-446, 1984.
63. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25:797-801, 1994.
64. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implications of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480, 1995.
65. Isacson C, Kessis TD, Hedrick L, Cho KR. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 56:669-674, 1996.
66. El-Labban NG, Osorio-Herrera E. Apoptotic bodies and abnormally dividing epithelial cells in squamous cell carcinoma. Histopathology 10:921-931, 1986.
67. Steel GG. Growth Kinetics of Tumors. London: Oxford University Press, 1977.
68. Deschner EE. Kinetics of Normal, Preneoplastic, and Neoplastic Colonic Epithelium. San Diego: Academic Press, 1990; 41.
69. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55:1811-1816, 1995.
70. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56:2422-2427, 1996.
71. Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 90:786-789, 1993.
72. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 79:189-192, 1994.
73. Oltvai Z, Milliman C, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog. Bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
74. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1993.
75. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang H-G, Reed JC. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hibrid system. Proc Natl Acad Sci USA 91:9238-9242, 1994.
76. Hanada M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of bcl-2 protein: Identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with with bax. J Biol Chem 270:11962-11968, 1995.
77. 2, displaces bax and promotes cell death. Cell 80:285-291, 1995.
78. Farrow SN, White JHM, Martinou I, Raven T, Pun K-T, Grinham CJ, Martinou J-C, Brown R. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature (Lond), 374:731-733, 1995.
79. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC. Induction of apoptosis by the Bcl-2 homologue Bak. Nature (Lond) 374:733-736, 1995.
80. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Ubansky SR, Tomei LD, Barr PJ. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature (Lond) 374:736-739, 1995.
81. Bodrug SE, Aime-Sempe C, Sato T, Krajewski S, Hanada M, Reed JC. Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: Evidence for a novel mechanism of regulating Bcl-2 family protein function. Cell Death Differ 2:173-182, 1995.
82. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, Craig RW. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-myc overexpression in Chinese chamster ovary cells. Cancer Res 54:6348-6352, 1994.
83. 2 repress a common pathway of cell death. J Exp Med 182:821-828, 1995.
84. Silvetsrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994.
85. s Gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 56:1965-1969, 1996.
86. Harris AL. Editorial: what does Bcl-2 mean in solid tumours friend or foe? Ann Oncol 5:388-390, 1994.
87. Krajewski S, Blomvqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Reed JC. Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995.
88. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener K, Wagener C, Kallinich B, Royer HD, Dorken B. Expression of the bcl-2 gene family in normal and malignant breast tissues: low bax-a expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60:854-859, 1995.
89. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
90. Sala A, Casella I, Grasso L, Bellon T, Reed JC, Miyashita T, Peschle C. Apoptotic response to oncogenic stimuli: Cooperative and antagonistic interactions between c-myb and the growth suppressor p53. Cancer Res 56:1991-1996, 1996.
91. Hass-Kogan DA, Kogan SC, Levi D, Dazin P, T Ang A, Fung Y-KT, Israel MA. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 14:461-472, 1995.
92. Haupt Y, Rowan S, Oren M. p53-mediated apoptosis in Hela cells can be overcome by excess pRB. Oncogene 10:1563-1571, 1995.
93. An B, Dou QP. Cleavage of retinoblastoma protein during apoptosis: An interleukin 1β-converting enzyme-like protease as candidate. Cancer Res 56:438-442, 1996.
94. Foster R, Zhao X, Day K, Swanson P, Humphrey P, Dean D, Day M. The retinoblastoma gene product mediates apoptosis of prostate epithelium. Proc Amer Assoc Cancer Res 37:28, 1996.
95. Warburg O. Uber den stoffwechsel der tumoren. Cambridge: Cambridge University Press, 1926.
96. Sevick EM, Jain RK. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia. Cancer Res 48:1202-1207, 1988.
97. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment. Cancer Res 49:6449-6465, 1989.
98. 2H NMR spectroscopy. Proc 10th Ann Mtg Soc Magn Reson Med 984, 1991.
99. Bhujwalla ZM, Tozer GM, Feld SB, Maxwell RJ, Griffiths JR. Energy metabolism of RIF-1 tumors following hydralazine. Radiother Oncol 19:281-291, 1990.
100. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343-366, 1991.
101. Griffiths JR. Are cancer cells acidic? Br J Cancer 64:425-427, 1991.
102. Gillies RJ, Liu Z, Bhujwalla ZM. 31P NMR measurement of extracellular pH in situ using 3-aminopropylphosphonate. Am J Physiol 267 (Cell Physiol 36):C195-C203, 1994.
103. Schlappack OK, Zimmermann A, Hill RP. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content, and MTX resistance of murine tumour cells. Int J Cancer 64:663-670, 1991.
104. Martinez-Zaguilen R, Seftor EA, Seftor REB, Chu Y-W, Gillies RJ, Hendrix MJC. Acidic pH enhances the invasive behaviour of human melanoma cells. Clin Exp Metastasis 14:176-186, 1996.
105. Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103 kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 267:11424-11430, 1992.
106. Park H, Lyons J, Auger E, Song C. Apoptosis in cancer cells caused by low pH environment. Proc Am Assoc Cancer Res 37:28, 1996.
107. Castle VP, Heidelberger JB, Ou X, Dole M, Nunez Z. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143:1543-1550, 1993.
108. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992.
109. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 9:3367-3370, 1994.
110. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol:40 2353-2362, 1990.
111. Eastman A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280, 1990.
112. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994.
113. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11:121-139, 1992.
114. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86:1286-1296, 1994.
115. L can cofer a multidrug resistance phenotype. Blood 86:1903-1910, 1995.
116. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31 kDa lactose-binding lectin in normal gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56:474-480, 1994.
117. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 10:111-120, 1992.
118. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: Association of the β3 subunit with tumor progression. Cancer Res 50:6757-6764, 1990.
119. McGregor BC, McGregor JL, Weiss LM, Wood GS, Hu CH, Boukerche H, Warnke RA. Presence of cytoadhesins (IIb-IIa-like glycoproteins) on human metastatic melanomas but not on benign melanocytes. Am J Clin Pathol 92:495-499, 1989.
120. vβ3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology (Oxford) 24:249-256, 1994.
121. Cheresh DA. The biological function of β3 integrins and other vitronectin receptors. In: Metcalf BW, Dalton BJ, Poste G, eds. Cellular Adhesion: Molecular Definition to Therapeutic Potential. New York: Plenum Press, 1994; 3-24.
122. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA. Requirement of the integrin β3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117:1101-1107, 1992.
123. vβ3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res 56:3103-3111, 1996.
124. Shibata M-A, Maroulakou I, Jorcyk CL, Gold LG, Ward JM, Green JE. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56:2998-3003, 1996.
125. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui P-Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793-799.
126. FAK) in invasive human tumors. Cancer Res 55:2752-2755.
127. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782-784, 1996.
128. Wang C-Y, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis potentiation by inhibition of NF-κB. Science 274:784-787, 1996.
129. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
130. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol Cell Biol 15:2809-2818, 1995.
131. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485-1488.
132. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16:1295-1304, 1996.
133. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78:773-785, 1994.
134. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90:3294-3298, 1993.
135. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 86:975-982, 1994.
136. Kerbel RS, Rak J, Kobayashi H, et al. Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Symp on Quantitative Biology: Molecular Genetics of Cancer 59:661-672, 1994.
137. Kerbel RS, St.Croix B, Rak J, et al. Is there a role for 'anti-adhesives' as chemosensitizers in the treatment of solid tumors by chemotherapy? Bulletin l'Institut Pasteur 92:248-256, 1995.
138. St.Croix B, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Hyaluronidase reverses adhesion-dependent multi-cellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst 88:1285-1296, 1996.
139. Frankel A, Glinsky GV, Mossine VV, Buckman R, Kerbel RS. Synthetic glycoamine analogs synergize with taxol and cisplatin in inducing programmed cell death in ovarian cancer cells. Proc Am Assoc Cancer Res 38, in press, 1997.